Ken Griffin Jounce Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.9 - $1.85 $61,789 - $127,011	68,655 Added 767.61%	77,599 $143,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $926,027 - $2.88 Million	-1,446,918 Reduced 99.39%	8,944 $9,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $652,483 - $1.18 Million	-239,005 Reduced 14.1%	1,455,862 $3.41 Million
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $18,723 - $51,289	-6,687 Reduced 0.39%	1,694,867 $5.14 Million
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $165,166 - $234,696	-27,482 Reduced 1.59%	1,701,554 $11.6 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $34,021 - $46,127	4,785 Added 0.28%	1,729,036 $14.4 Million
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $1.19 Million - $2.06 Million	-236,350 Reduced 12.05%	1,724,251 $12.8 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $355 - $575	54 Added 0.0%	1,960,601 $13.3 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $1.54 Million - $3.18 Million	229,198 Added 13.24%	1,960,547 $20.1 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $10.8 Million - $17.5 Million	1,694,224 Added 4563.57%	1,731,349 $12.1 Million
Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $1.91 Million - $4.56 Million	-416,777 Reduced 91.82%	37,125 $303,000
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $1.72 Million - $3.12 Million	412,056 Added 984.7%	453,902 $3.13 Million
Q1 2020 May 15, 2020	BUY	$2.91 - $8.7 $87,969 - $263,001	30,230 Added 260.24%	41,846 $198,000
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $2,661 - $8,721	947 Added 8.88%	11,616 $101,000
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $51,065 - $75,601	-15,335 Reduced 58.97%	10,669 $35,000
Q2 2019 Aug 14, 2019	SELL	$4.3 - $6.73 $226,648 - $354,731	-52,709 Reduced 66.96%	26,004 $129,000
Q1 2019 May 15, 2019	SELL	$3.43 - $6.87 $26,908 - $53,895	-7,845 Reduced 9.06%	78,713 $0
Q4 2018 Feb 14, 2019	SELL	$2.69 - $6.71 $357,425 - $891,571	-132,872 Reduced 60.55%	86,558 $291,000
Q3 2018 Nov 13, 2018	SELL	$6.5 - $8.37 $2.05 Million - $2.64 Million	-314,941 Reduced 58.94%	219,430 $0
Q2 2018 Aug 10, 2018	BUY	$7.27 - $21.88 $1.76 Million - $5.29 Million	241,786 Added 82.64%	534,371 $0
Q1 2018 May 11, 2018	BUY	$13.4 - $28.4 $3.92 Million - $8.31 Million	292,585 New	292,585 $6.54 Million

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account